Chemoimmunotherapy with rituximab (R-chemo) or obinutuzumab (G-chemo) is standard of
care for patients with previously untreated symptomatic or high-tumor-burden follicular …

Defining the role of high-dose therapy with autologous stem cell rescue in the therapeutic
algorithm of follicular lymphoma remains a major challenge. In contrast to the acknowledged …

E1496 is a phase III trial designed to evaluate the ability of 2 years (yr) of maintenance
rituximab (MR) to prolong progression-free survival (PFS) after CVP (cyclophosphamide 1 …

Purpose Optimal therapy of follicular lymphoma (FL) is not defined. We analyzed a large
prospective cohort study to identify current demographics and patterns of care of FL in the …

Background The purpose of this study was to identify prognostic parameters for patients with
follicular lymphoma (FL) in first progression/relapse. These would be useful for selection of …

Abstract Abstract 97 Background: There is no consensus or standard of care for front-line
therapy for FL as demonstrated by our initial publication of the National LymphoCare Study …

Single-center experiences have shown that intensified treatments with autologous
transplantation are a promising therapeutic strategy for patients with high-risk follicle-center …

Background: Follicular lymphoma (FL) tumors are infiltrated with antitumor T cells, however,
their function is impaired by immune checkpoints such as PD-1/PD-ligand pathway. Blocking …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …

Follicular lymphomas are characterized by relatively long median survivals and a
continuous pattern of relapse. The heterogeneity in these diseases is increasingly …